 Napo EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome crofelemer has received orphan-drug designation from the US FDA for SBS Merger of Napo EU Dragon SPAC expected to be effective within approximately 80 days, with related future SBS license and milestone fees totaling up to 12.5 million MILAN, ITALY and SAN FRANCISCO, CA ACCESSWIRE July 19, 2021 Dragon SPAC S.p.A. and Napo EU S.p.A. 